Using fluorodeoxythymidine to monitor anti-egfr inhibitor therapy in squamous cell carcinoma xenografts

Head and Neck

Volumn 30, Issue 6, 2008, Pages 790-799

  Atkinson, David M ^a   Clarke, Michelle J ^b   Mladek, Ann C ^b   Carlson, Brett L ^b   Trump, David P ^b   Jacobson, Mark S ^b   Kemp, Brad J ^b   Lowe, Val J ^b   Sarkaria, Jann N ^b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b MAYO CLINIC   (United States)

Author keywords

Anti EGFR inhibitor therapy; Cetuximab; Erlotinib; Fluorodeoxythymidine (FLT); Squamous cell carcinoma xenografts

Indexed keywords

3' FLUOROTHYMIDINE; 3' FLUOROTHYMIDINE F 18; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; ERLOTINIB; FLUORINE; PLACEBO; THYMIDINE KINASE 1;

ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INHIBITION; CELL PROLIFERATION; DRUG MONITORING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SQUAMOUS CELL CARCINOMA; TUMOR XENOGRAFT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, SQUAMOUS CELL; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; FEMALE; FLUORINE RADIOISOTOPES; HEAD AND NECK NEOPLASMS; HUMANS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; POSITRON-EMISSION TOMOGRAPHY; PROTEIN KINASE INHIBITORS; QUINAZOLINES; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 46249132392     PISSN: 10433074     EISSN: 10970347     Source Type: Journal    
DOI: 10.1002/hed.20770     Document Type: Article

References (19)

1. Vesselle H, Grierson J, Muzi M, et al. In vivo validation of 3′deoxy-3′-[(18)F]fluorothymidine ([(18)F]FLT) as a proliferation imaging tracer in humans: correlation of [(18)F]FLT uptake by positron emission tomography with Ki-67 immunohistochemistry and flow cytometry in human lung tumors. Clin Cancer Res 2002;8:3315-3323.
2. Buck AK, Schirrmeister H, Hetzel M, et al. 3-Deoxy-3-[18F] fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002;62:3331-3334.
3. Francis DL, Freeman A, Visvikis D, et al. In vivo imaging of cellular proliferation in colorectal cancer using positron emission tomography. Gut 2003;52:1602-1606.
4. Wagner M, Seitz U, Buck A, et al. 3′-[18F]fluoro-3′-deox- ythymidine ([18F]-FLT) as positron emission tomography tracer for imaging proliferation in a murine B-cell lymphoma model and in the human disease. Cancer Res 2003;63:2681-2687.
5. Munch-Petersen B, Cloos L, Tyrsted G, Eriksson S. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides. J Biol Chem 1991;266:9032-9038.
6. Langen P, Kowollik G, Etzold G, Venner H, Reinert H. The phosphorylation of 3′-deoxy-3′-fluorothymidine and its incorporation into DNA in a cellfree system from tumor cells. Acta Biol Med Ger 1972;29:483-494.
7. Shields AF, Grierson JR, Dohmen BM, et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 1998;4:1334-1336.
8. Schinazi RF, Peck A, Sommadossi JP. Substrate specificity of Escherichia coli thymidine phosphorylase for py-rimidine nucleosides with anti-human immunodeficiency virus activity. Biochem Pharmacol 1992;44:199-204.
9. Schwartz JL, Tamura Y, Jordan R, Grierson JR, Krohn KA. Monitoring tumor cell proliferation by targeting DNA synthetic processes with thymidine and thymidine analogs. J Nucl Med 2003;44:2027-2032.
10. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL. Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002;43:1210-1217.
11. Wang N, He Q, Skog S, Eriksson S, Tribukait B. Investigation on cell proliferation with a new antibody against thymidine kinase 1. Anal Cell Path 2001;23:11-19.
12. Jeong MH, Jin YH, Kang EY, et al. The modulation of radiation-induced cell death by genistein in K562 cells: activation of thymidine kinase 1. Cell Res 2004;14:295-302.
13. Machulla H-J, Blocher A, Kuntzsch M, Piert M, Wei R, Grierson J. Simplified labeling approach for synthesizing 3′-deoxy-3′-[18F] fluorothymidine ([18F]FLT). J Radioanal Nucl Chem 2000;243:843-846.
14. 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med 2004;45:695-700.
15. Huang SM, Harari PM. Modulation of radiation response after epidermal growth factor receptor blockade in squamous cell carcinomas: inhibition of damage repair, cell cycle kinetics, and tumor angiogenesis. Clin Cancer Res 2000;6:2166-2174.
16. Jimeno A, Belen Rubio-Viqueira B, Amador ML, et al. Epidermal growth factor receptor dynamics influences response to epidermal growth factor receptor targeted agents. Cancer Res 2005;65:3003-3010.
17. Waldherr C, Mellinghoff IK, Tran C, et al. Monitoring antiproliferative responses to kinase inhibitor therapy in mice with 3′-deoxy-3′-18F- fluorothymidine PET. J Nucl Med 2005;46:114-120.
18. Dittmann H, Dohmen BM, Kehlbach R, et al. Early changes in [18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 2002;29: 1462-1469.
19. Perumal M, Pillai RG, Barthel H, et al. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidylate synthase inhibition by positron emission tomography. Cancer Res 2006; 66:8558-8564.